Literature DB >> 23434070

Infantile facioscapulohumeral muscular dystrophy revisited: Expansion of clinical phenotypes in patients with a very short EcoRI fragment.

Tai-Heng Chen1, Yu-Hung Lai, Pei-Lun Lee, Jong-Hau Hsu, Kanako Goto, Yukiko K Hayashi, Ichizo Nishino, Chin-Wen Lin, Hsiang-Hung Shih, Chao-Ching Huang, Wen-Chen Liang, Wen-Fu Wang, Yuh-Jyh Jong.   

Abstract

Contrary to the classical form, infantile facioscapulohumeral muscular dystrophy (FSHD) usually denotes a severe phenotype and is frequently associated with extramuscular involvements. To elucidate the genotype-phenotype correlation in this severe subgroup, we identified a cohort of nine patients with infantile FSHD who also carried a very short (10-13kb) EcoRI fragment. Their current age ranged from 8 to 33 years and age of onset ranged from 0.4 to 5 years. One patient even manifested his first FSHD-related symptoms at as early as 5 months of age, including inability to smile, poor response to call, and infantile spasms. To date, four patients were wheelchair-bound and six patients had asymmetric weakness. Sensorineural hearing loss and abnormal fundoscopic findings were observed in eight and all of patients respectively. Three with the smallest EcoRI fragments (10-11kb, with normal length being 50-300kb) had mental retardation. Two of these had epilepsy. Cardiac arrhythmias were found in five patients. Restrictive ventilatory defects were observed in seven patients, with one progressing to chronic respiratory failure. Two had swallowing difficulties; one of these required gastrostomy. We identified several rarely reported phenotypes in infantile FSHD, including cardiac arrhythmia, respiratory insufficiency, and swallowing difficulties. There seems to be a correlation between the severity of phenotype and the very short EcoRI fragment in the chromosome 4q35 region. We conclude that the high frequency of multi-organ involvements in this severe FSHD variant suggests the need for an early and multidisciplinary intervention.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23434070     DOI: 10.1016/j.nmd.2013.01.005

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  21 in total

1.  Early onset as a marker for disease severity in facioscapulohumeral muscular dystrophy.

Authors:  Rianne J M Goselink; Karlien Mul; Caroline R van Kernebeek; Richard J L F Lemmers; Silvère M van der Maarel; Tim H A Schreuder; Corrie E Erasmus; George W Padberg; Jeffrey M Statland; Nicol C Voermans; Baziel G M van Engelen
Journal:  Neurology       Date:  2018-12-19       Impact factor: 9.910

Review 2.  Facioscapulohumeral muscular dystrophy as a model for epigenetic regulation and disease.

Authors:  Charis L Himeda; Takako I Jones; Peter L Jones
Journal:  Antioxid Redox Signal       Date:  2014-12-04       Impact factor: 8.401

Review 3.  Facioscapulohumeral muscular dystrophy (FSHD) molecular diagnosis: from traditional technology to the NGS era.

Authors:  Stefania Zampatti; Luca Colantoni; Claudia Strafella; Rosaria Maria Galota; Valerio Caputo; Giulia Campoli; Giulia Pagliaroli; Stefania Carboni; Julia Mela; Cristina Peconi; Stefano Gambardella; Raffaella Cascella; Emiliano Giardina
Journal:  Neurogenetics       Date:  2019-03-25       Impact factor: 2.660

4.  A multinational study on motor function in early-onset FSHD.

Authors:  Jean K Mah; Jia Feng; Marni B Jacobs; Tina Duong; Kate Carroll; Katy de Valle; Cara L Carty; Lauren P Morgenroth; Michela Guglieri; Monique M Ryan; Paula R Clemens; Mathula Thangarajh; Richard Webster; Edward Smith; Anne M Connolly; Craig M McDonald; Peter Karachunski; Mar Tulinius; Amy Harper; Avital Cnaan; Yi-Wen Chen
Journal:  Neurology       Date:  2018-03-14       Impact factor: 9.910

5.  Dominant lethal pathologies in male mice engineered to contain an X-linked DUX4 transgene.

Authors:  Abhijit Dandapat; Darko Bosnakovski; Lynn M Hartweck; Robert W Arpke; Kristen A Baltgalvis; Derek Vang; June Baik; Radbod Darabi; Rita C R Perlingeiro; F Kent Hamra; Kalpna Gupta; Dawn A Lowe; Michael Kyba
Journal:  Cell Rep       Date:  2014-08-28       Impact factor: 9.423

6.  Validation of Optical Genome Mapping for the Molecular Diagnosis of Facioscapulohumeral Muscular Dystrophy.

Authors:  Aaron A Stence; Jon G Thomason; Jonathan A Pruessner; Ramakrishna R Sompallae; Anthony N Snow; Deqin Ma; Steven A Moore; Aaron D Bossler
Journal:  J Mol Diagn       Date:  2021-08-09       Impact factor: 5.568

7.  Cardiac Involvement in Facioscapulohumeral Muscular Dystrophy (FSHD).

Authors:  Allison Ducharme-Smith; Stefan Nicolau; C Anwar A Chahal; Kirstie Ducharme-Smith; Shujah Rehman; Keerthi Jaliparthy; Nadeem Khan; Christopher G Scott; Erik K St Louis; Teerin Liewluck; Virend K Somers; Grace Lin; Peter A Brady; Margherita Milone
Journal:  Front Neurol       Date:  2021-05-24       Impact factor: 4.003

8.  Identifying diagnostic DNA methylation profiles for facioscapulohumeral muscular dystrophy in blood and saliva using bisulfite sequencing.

Authors:  Takako I Jones; Chi Yan; Peter C Sapp; Diane McKenna-Yasek; Peter B Kang; Colin Quinn; Johnny S Salameh; Oliver D King; Peter L Jones
Journal:  Clin Epigenetics       Date:  2014-10-29       Impact factor: 6.551

9.  Facioscapulohumeral dystrophy in children: design of a prospective, observational study on natural history, predictors and clinical impact (iFocus FSHD).

Authors:  Rianne J M Goselink; Tim H A Schreuder; Karlien Mul; Nicol C Voermans; Maaike Pelsma; Imelda J M de Groot; Nens van Alfen; Bas Franck; Thomas Theelen; Richard J Lemmers; Jean K Mah; Silvère M van der Maarel; Baziel G van Engelen; Corrie E Erasmus
Journal:  BMC Neurol       Date:  2016-08-17       Impact factor: 2.474

10.  Effects of weakness of orofacial muscles on swallowing and communication in FSHD.

Authors:  Karlien Mul; Kiera N Berggren; Mattie Y Sills; Ayla McCalley; Baziel G M van Engelen; Nicholas E Johnson; Jeffrey M Statland
Journal:  Neurology       Date:  2019-01-25       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.